文献速递骨软组织肉瘤与黑色素瘤

安罗替尼联合特瑞普利单抗治疗晚期骨与软组织肉瘤的II期研究

Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial.
PubMed 文献 · Eur J Cancer · 2026-06-06

这项多中心单臂II期试验评估安罗替尼联合特瑞普利单抗在晚期骨与软组织肉瘤(含超罕见亚型)中的疗效与安全性。68例可评估患者确认ORR为29%,DCR为90%,中位PFS 7.0个月,中位OS 27.0个月;软组织超罕见肉瘤亚组ORR达39%。毒性可控,基线单核细胞计数与生存相关。

要点

  • 安罗替尼联合特瑞普利单抗在晚期肉瘤中ORR 29%、DCR 90%,软组织超罕见亚组ORR 39%。
  • 中位PFS 7.0个月、中位OS 27.0个月,≥3级治疗相关不良事件以高血压、手足综合征常见。
  • 基线单核细胞计数低与应答及更长PFS、OS相关,提示潜在无创生物标志物。

核心结论

  • 安罗替尼联合特瑞普利单抗在经治、组织学多样的晚期肉瘤中显示有临床意义的抗肿瘤活性,毒性可管理。

研究设计与样本

  • 中国四中心单臂II期临床试验,纳入70例晚期骨与软组织肉瘤患者,68例可评估疗效。
  • 治疗方案为安罗替尼12 mg(第1–14天)联合特瑞普利单抗240 mg(第1天),每3周一次。
  • 主要终点为RECIST 1.1标准评估的客观缓解率(ORR),次要终点包括疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)和安全性。

主要发现

  • 中位随访29.6个月时,确认ORR为29%(95%CI:19–42%),DCR为90%(95%CI:80–96%)。
  • 中位PFS为7.0个月,中位OS为27.0个月。
  • 软组织超罕见肉瘤亚组(n=31)ORR为39%,中位PFS为11.0个月。
  • 治疗相关≥3级不良事件包括高血压(15.7%)、手足综合征(12.9%)和高甘油三酯血症(7.1%)。
  • 探索性事后分析显示基线单核细胞计数与PFS和OS独立相关,应答者基线单核细胞显著低于非应答者。

关键数值与推荐

  • 确认ORR 29%(95%CI:19–42%),DCR 90%(95%CI:80–96%)。
  • 软组织超罕见肉瘤亚组ORR 39%,中位PFS 11.0个月。
  • ≥3级治疗相关不良事件:高血压15.7%、手足综合征12.9%、高甘油三酯血症7.1%。

临床怎么用

  • 对于经治的晚期骨与软组织肉瘤(包括超罕见亚型),可考虑安罗替尼联合特瑞普利单抗方案。
  • 治疗期间需重点监测高血压、手足综合征和高甘油三酯血症等不良事件。
  • 基线单核细胞计数或可作为预测疗效与生存的参考指标,但需进一步验证。

局限性

  • 单臂设计,无对照组,结论为探索性,需随机对照试验验证。
  • 样本量有限(70例入组,68例可评估),组织学亚型多样。
  • 单核细胞计数为事后分析,尚未前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options for advanced sarcomas, particularly ultra-rare sarcomas (URS), remain limited. This study evaluated the activity and safety of anlotinib combined with toripalimab in a histologically diverse sarcoma population. METHODS: This single-arm, phase 2 clinical trial was conducted at four centers in China. Participants received anlotinib (12 mg on days 1-14) in combination with toripalimab (240 mg on day 1) every 3 weeks. The primary endpoint was objective response rate (ORR) by RECIST 1.1. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Of 70 enrolled patients, 68 were evaluable for activity. The cohort included 34 (48.6%) patients with URS. At a median follow-up of 29.6 months, confirmed ORR was 29% (95% CI: 19-42%) and DCR was 90% (95% CI: 80-96%). Median PFS was 7.0 months and median OS was 27.0 months. In patients with soft-tissue URS (n = 31), ORR was 39% and median PFS was 11.0 months. Treatment-related grade ≥ 3 adverse events included hypertension (15.7%), hand-foot syndrome (12.9%), and hypertriglyceridemia (7.1%). Exploratory post-hoc analysis identified baseline monocyte count was independently associated with PFS and OS; responders had significantly lower baseline monocytes than non-responders. CONCLUSIONS: These single-arm, exploratory findings demonstrate clinically promising anti-tumor activity for anlotinib plus toripalimab with manageable toxicity in heavily pretreated, histologically diverse advanced sarcomas, highlighting its potential in URS and identifying monocytes as a pragmatic, non-invasive biomarker worthy of further validation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pan Q, Xu B, Zhang L, et al. Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial. Eur J Cancer. 2026. PMID: 42258994. doi:10.1016/j.ejca.2026.116871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。